Alnylam Pharma (ALNY) Tops Q1 EPS by 65c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Alnylam Pharmaceuticals (ALNY) PT Raised to $128 at BMO Capital
May 1, 2019 12:59 PM EDTBMO Capital analyst Do Kim raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $128.00 (from $126.00) while maintaining a Outperform rating following Q1 results.
The analyst commented, "We raise our Onpattro projections and target price to $128 from $126, as 1Q19 sales beat our and... More
